Tearsheet

BioLife Solutions (BLFS)

Market Price (12/28/2025): $24.89 | Market Cap: $1.2 Bil
Sector: Health Care | Industry: Health Care Supplies

BioLife Solutions (BLFS)

Market Price (12/28/2025): $24.89
Market Cap: $1.2 Bil
Sector: Health Care
Industry: Health Care Supplies

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 88%	Weak multi-year price returns 3Y Excs Rtn is -46%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -20 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -20%
1	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11%		Expensive valuation multiples P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 71x
2	Low stock price volatility Vol 12M is 49%		Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 27%
3	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Biopharmaceutical R&D, Show more.		Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.4%
4			Key risks BLFS key risks include [1] high customer concentration, Show more.

0	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 88%
1	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 17%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11%
2	Low stock price volatility Vol 12M is 49%
3	Megatrend and thematic drivers Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Biopharmaceutical R&D, Show more.
4	Weak multi-year price returns 3Y Excs Rtn is -46%
5	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -20 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -20%
6	Expensive valuation multiples P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 71x
7	Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 27%
8	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.4%
9	Key risks BLFS key risks include [1] high customer concentration, Show more.

Valuation, Metrics & Events

	12/28/25	2024	2023	2022	2021
Share Price CYE	$24.89	$25.96	$16.25	$18.20	$37.27
Market Cap CYE ($ Bil)	1.2	1.2	0.7	0.8	2.1
Total Debt ($ Bil)	0.0	0.0	0.0	0.0	0.0
Total Cash ($ Bil)	0.1	0.1	0.0	0.1	0.1
Enterprise Value ($ Bil)	1.1	1.2	0.7	0.8	2.1
Valuation Ratios
P/S TTM	11.9	14.5	9.4	10.1	13.3
P/EBIT TTM	-59.5	-167.8	-27.7	-72.4	-51.7
P/E TTM	-372.1	-59.2	-10.4	-5.5	-177.7
P/FCF TTM	112.9	243.9	-37.6	-41.0	-122.0
Sector Ratios
P/S TTM (Sector)	4.4	3.5	3.9	4.5	7.1
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4	-1.3	-2.6
P/E TTM (Sector)	-1.7	-1.5	-1.5	-1.3	-2.8
P/FCF TTM (Sector)	-1.5	-1.4	-1.4	-1.5	-3.2

	12/28/25	2024	2023
Share Price CYE	$24.89	$25.96	$16.25
Market Cap CYE ($ Bil)	1.2	1.2	0.7
Total Debt ($ Bil)	0.0	0.0	0.0
Total Cash ($ Bil)	0.1	0.1	0.0
Enterprise Value ($ Bil)	1.1	1.2	0.7
Valuation Ratios
P/S TTM	11.9	14.5	9.4
P/EBIT TTM	-59.5	-167.8	-27.7
P/E TTM	-372.1	-59.2	-10.4
P/FCF TTM	112.9	243.9	-37.6
Sector Ratios
P/S TTM (Sector)	4.4	3.5	3.9
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4
P/E TTM (Sector)	-1.7	-1.5	-1.5
P/FCF TTM (Sector)	-1.5	-1.4	-1.4

	BLFS	S&P 500
REVENUE GROWTH	VERY GOOD
Rev LTM ($ Bil)	0.1
Rev Chg Q	31.2%	7.3%
Rev Chg LTM	87.5%	6.1%
Rev Chg 3Y Avg	9.3%	5.5%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.0
CFO LTM ($ Bil)	0.0
Net Inc LTM ($ Bil)	-0.0
Op Mgn LTM	-20.0%	18.8%
CFO/Rev LTM	16.8%	20.4%
Net Inc Mgn	-3.2%	13.1%
VALUATION	VERY HIGH
P/S	11.9	3.3
P/CFO	70.8	15.8
P/FCF	112.9	20.7
P/E	-372.1	23.7
STABILITY	VERY GOOD
Debt/Equity	0.02	0.21
Cash/Assets	0.20	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Number of Customers	over 2,500	1012024	Link
Number of Issued Patents	37	1012024	Link
Number of Pending Patent Applications	28	1012024	Link
Recurring Revenue Percentage	approximately 65%	11292023	Link
Market Share in Commercially Sponsored CGT Trials in the US	70%+	10012025	Link
Number of Approved Cell and Gene Therapies Using BioLife Media	17	12312024	Link
Cumulative U.S. FDA Master File Cross References for Biopreservation Media	769	12312024	Link

Upcoming
3/02/2026	Earnings Release	Rev: - EPS: -

BLFS Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Here are five key points explaining BioLife Solutions' (BLFS) stock movement from August 31, 2025, to today:

1. BioLife Solutions reported a significant miss on its Q2 2025 Earnings Per Share (EPS), with a reported -$0.33 compared to a consensus estimate of -$0.02.

2. The company's Q2 2025 GAAP net loss was primarily impacted by a $15.5 million non-cash In-Process Research and Development (IPR&D) expense stemming from the PanTHERA CryoSolutions acquisition.

3. Despite improvements, analyst sentiment in October 2025 suggested that BioLife Solutions' valuation remained "a little steep," potentially leading to investor hesitation and limiting upward stock movement.

4. Projections for 2025 indicated only modest growth for the Evo and Thaw platform, with expected year-over-year growth ranging from 3% to 15%, potentially reflecting slower expansion in that segment.

5. Concerns persisted regarding BioLife Solutions' continued GAAP operating losses, even though they were reduced, contributing to a cautious outlook among investors.

Stock Movement Drivers

Fundamental Drivers

The 0.8% change in BLFS stock from 9/27/2025 to 12/27/2025 was primarily driven by a 7.1% change in the company's Total Revenues ($ Mil).

	9272025	12272025	Change
Stock Price ($)	24.70	24.90	0.81%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	93.47	100.14	7.14%
P/S Multiple	12.63	11.92	-5.66%
Shares Outstanding (Mil)	47.80	47.93	-0.27%
Cumulative Contribution			0.81%

LTM = Last Twelve Months as of date shown

Market Drivers

9/27/2025 to 12/27/2025

	Return	Correlation
BLFS	0.8%
Market (SPY)	4.3%	44.8%
Sector (XLV)	15.2%	46.2%

Fundamental Drivers

The 15.9% change in BLFS stock from 6/28/2025 to 12/27/2025 was primarily driven by a 14.1% change in the company's Total Revenues ($ Mil).

	6282025	12272025	Change
Stock Price ($)	21.49	24.90	15.87%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	87.76	100.14	14.11%
P/S Multiple	11.54	11.92	3.24%
Shares Outstanding (Mil)	47.13	47.93	-1.68%
Cumulative Contribution			15.84%

LTM = Last Twelve Months as of date shown

Market Drivers

6/28/2025 to 12/27/2025

	Return	Correlation
BLFS	15.9%
Market (SPY)	12.6%	45.8%
Sector (XLV)	17.0%	45.0%

Fundamental Drivers

The -6.4% change in BLFS stock from 12/27/2024 to 12/27/2025 was primarily driven by a -48.2% change in the company's P/S Multiple.

	12272024	12272025	Change
Stock Price ($)	26.59	24.90	-6.36%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	53.40	100.14	87.53%
P/S Multiple	22.99	11.92	-48.17%
Shares Outstanding (Mil)	46.18	47.93	-3.79%
Cumulative Contribution			-6.49%

LTM = Last Twelve Months as of date shown

Market Drivers

12/27/2024 to 12/27/2025

	Return	Correlation
BLFS	-6.4%
Market (SPY)	17.0%	51.7%
Sector (XLV)	13.8%	46.5%

Fundamental Drivers

The 46.9% change in BLFS stock from 12/28/2022 to 12/27/2025 was primarily driven by a 155.2% change in the company's P/S Multiple.

	12282022	12272025	Change
Stock Price ($)	16.95	24.90	46.90%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	154.81	100.14	-35.31%
P/S Multiple	4.67	11.92	155.18%
Shares Outstanding (Mil)	42.65	47.93	-12.37%
Cumulative Contribution			44.65%

LTM = Last Twelve Months as of date shown

Market Drivers

12/28/2023 to 12/27/2025

	Return	Correlation
BLFS	48.9%
Market (SPY)	48.0%	45.8%
Sector (XLV)	17.9%	41.1%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
BLFS Return	147%	-7%	-51%	-11%	60%	-2%	57%
Peers Return	16%	38%	-12%	21%	26%	16%	150%
S&P 500 Return	16%	27%	-19%	24%	23%	18%	114%
Monthly Win Rates [3]
BLFS Win Rate	67%	42%	42%	42%	50%	42%
Peers Win Rate	52%	65%	42%	68%	57%	52%
S&P 500 Win Rate	58%	75%	42%	67%	75%	73%
Max Drawdowns [4]
BLFS Max Drawdown	-48%	-26%	-72%	-51%	-7%	-20%
Peers Max Drawdown	-34%	-5%	-26%	-7%	-9%	-23%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)

How Low Can It Go

Unique Key	Event	BLFS	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-85.1%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	573.0%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-50.9%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	103.7%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	92 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-62.7%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	168.2%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	633 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-88.2%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	750.0%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	215 days	1,480 days

Compare to HPQ, HPE, IBM, CSCO, AAPL

In The Past

BioLife Solutions's stock fell -85.1% during the 2022 Inflation Shock from a high on 9/1/2021. A -85.1% loss requires a 573.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About BioLife Solutions (BLFS)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

AI Analysis | Feedback

ASML for cell and gene therapy materials.
NVIDIA for biological preservation in advanced therapies.
Thermo Fisher Scientific, but exclusively focused on biological cold chain and preservation.

AI Analysis | Feedback

CryoStor® and HypoThermosol® Biopreservation Media: These proprietary solutions protect cells, tissues, and organs during freezing, storage, and transport.
ThawSTAR® Automated Thawing Devices: These devices provide standardized, water-free thawing for cryopreserved cell and gene therapies.
evo.is® Smart Shippers: These cloud-connected cold chain management containers offer real-time monitoring and data logging for temperature-sensitive biological materials.

AI Analysis | Feedback

BioLife Solutions (BLFS) primarily sells its biopreservation tools and services to other companies and institutions within the life sciences and biopharmaceutical sectors. This indicates a Business-to-Business (B2B) model.

While BioLife Solutions does not publicly disclose the specific names of its major individual customer companies due to confidentiality and competitive reasons (as is common in this industry), their financial filings indicate that their top 10 customers account for approximately 35% of their total revenue. They frequently state that they serve the vast majority of the leading companies in the cell and gene therapy sector.

Based on their market focus and product offerings, their major customer segments include:

Biopharmaceutical Companies (especially Cell and Gene Therapy Developers): This is BioLife Solutions' core customer base. These companies, which include both large public pharmaceutical firms and specialized biotech companies, develop and commercialize advanced cell and gene therapies. BioLife Solutions' biopreservation media (CryoStor®, HypoThermosol®) and thaw devices (ThawSTAR®) are crucial for maintaining the viability of biological materials throughout the development, manufacturing, and distribution of these therapies. Examples of the types of public companies that operate in this space (and are likely customers, though not specifically named as major clients by BLFS) include:
- Gilead Sciences, Inc. (GILD) (via Kite Pharma)
- Novartis AG (NVS)
- Bristol Myers Squibb Company (BMY)
- bluebird bio, Inc. (BLUE)
- Moderna, Inc. (MRNA)
- Vertex Pharmaceuticals Incorporated (VRTX)
It is important to note that BLFS serves a wide array of companies in this sector, and the examples above are illustrative of the types of public companies that are likely customers, rather than a definitive list of specific named major clients.
Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs): These organizations provide outsourced services to biopharmaceutical companies, including research, development, manufacturing, and logistics support for cell and gene therapies. They rely on BioLife Solutions' products to ensure the integrity and viability of biological materials in their workflows.
Biobanks and Academic/Research Institutions: These entities are involved in the collection, processing, storage, and distribution of biological samples for research, clinical studies, and future therapeutic applications. BioLife Solutions' biopreservation solutions are essential for the long-term preservation and quality assurance of these valuable samples.

AI Analysis | Feedback

null

AI Analysis | Feedback

Roderick de Greef, Chairman and Chief Executive Officer

Roderick de Greef was appointed Chairman and Chief Executive Officer of BioLife Solutions in 2023. He previously served as the company's Chief Financial Officer from May 2016 to November 2021, and subsequently as President and Chief Operating Officer until January 2023, when he retired from management and rejoined the board of directors. Prior to his executive roles at BioLife Solutions, Mr. de Greef accumulated over 20 years of experience as Chief Financial Officer for various public and private life science and medical technology companies. He has been actively involved in numerous domestic and international mergers and acquisitions (M&A) and financing transactions throughout his career. Mr. de Greef has also served on the boards of several public and private companies, including Endologix, Cambridge Heart, Cardiac Science, and Elephant Talk Communications.

Troy Wichterman, Chief Financial Officer

Troy Wichterman was promoted to Chief Financial Officer of BioLife Solutions in November 2021. He joined the company in 2015 as a financial analyst and advanced through various finance and accounting positions, including Vice President of Finance since November 2019. Mr. Wichterman has played an integral role in six acquisitions for BioLife Solutions. Before joining BioLife Solutions, his experience included financial roles at Ventas, Heitman, and PricewaterhouseCoopers.

Michael Rice, Former Chairman and Chief Executive Officer

Michael Rice served as President and Chief Executive Officer of BioLife Solutions from August 2006 and as Chairman from August 2007, for over 17 years. He is now a strategic advisor and board member to several life science tools startups. Under his leadership, BioLife Solutions experienced significant growth, with revenue increasing from under $1 million to nearly $150 million and its market capitalization peaking at $2 billion. Prior to BioLife Solutions, Mr. Rice held senior roles at AMI Semiconductor, Cardiac Science, TEGRIS Corporation, and Physio Control Corporation. He was also a cohead of Health Care Investment Banking at Canaccord Adams and a managing director at Think Equity Partners, where he managed Healthcare Capital Markets and structured numerous transactions. Additionally, he is a founding partner of LifeSci Advisors LLC and LifeSci Capital LLC, a research-driven investment bank.

Aby J. Mathew, Ph.D., Executive Vice President and Chief Scientific Officer

Dr. Aby J. Mathew holds the position of Executive Vice President and Chief Scientific Officer at BioLife Solutions. He was a key member of the founding team of BioLife Solutions and is a co-developer of the company's proprietary biopreservation media solutions, including HypoThermosol® and CryoStor®. Dr. Mathew is a co-inventor on multiple issued and pending patents related to methods, devices, and formulations for the preservation of cells, tissues, and organs.

Karen Foster, Chief Quality and Operations Officer

Karen Foster has served as the Chief Quality Officer at BioLife Solutions since December 2019 and is also listed as Chief Quality and Operations Officer. She initially joined the company as Vice President of Operations in April 2016. Before her tenure at BioLife Solutions, Ms. Foster was the Vice President of Laboratory Operations and Site Leader at ViaCord, LLC, a family cord blood bank and a subsidiary of PerkinElmer Inc. Her extensive career, spanning 25 years, includes managing manufacturing and quality operations for prominent companies such as Pfizer, Inc. (formerly Pharmacia Corporation) and Amersham Pharmacia Biotech, Inc. (formerly Pharmacia Biotech, Inc.).

AI Analysis | Feedback

The key risks to BioLife Solutions (BLFS) business primarily revolve around its customer concentration, challenges in achieving consistent profitability, and stock price volatility influenced by a major shareholder.

Customer Concentration and Reliance on the Volatile Cell and Gene Therapy Clinical Trial Ecosystem: BioLife Solutions' business, particularly its high-margin biopreservation media, is heavily dependent on a concentrated customer base within the cell and gene therapy (CGT) industry. Approximately 80% of the biopreservation media (BPM) revenue comes from the top 20 customers. The company's success is directly tied to the highly volatile clinical trial ecosystem, meaning that delays or failures in key customer clinical trials could significantly hinder revenue growth.
Lack of Consistent Profitability: Despite demonstrating strong revenue growth, BioLife Solutions has faced challenges in achieving consistent profitability, as evidenced by negative earnings per share (EPS) and return on equity (ROE). This ongoing struggle with profitability is attributed to factors such as high operating expenses and a consolidated gross margin that is lower than its core potential.
Stock Price Volatility and Influence of a Major Shareholder: The trading price and volume of BioLife Solutions' common stock have been highly volatile and are subject to significant fluctuations. Furthermore, a substantial percentage of the company's outstanding common stock is held by one stockholder, Casdin Capital, LLC, which owned 18.6% of the shares as of December 31, 2024. This significant ownership grants Casdin Capital, LLC considerable influence over BioLife Solutions' corporate actions and decision-making.

AI Analysis | Feedback

The emergence and increasing adoption of decentralized or point-of-care manufacturing models for cell and gene therapies. This trend aims to reduce the need for long-distance cold chain logistics and large-scale centralized storage by producing therapies closer to the patient, thereby diminishing the addressable market for BioLife Solutions' evo cold chain solutions and SciSafe storage services for certain therapy types.

AI Analysis | Feedback

BioLife Solutions (BLFS) operates in several significant addressable markets related to cell and gene therapy, biopreservation, and regenerative medicine:

The global biopreservation solutions market was valued at $2.3 billion in 2023 and is projected to grow to $4.7 billion by 2030.
The global cell and gene therapy (CGT) market, a key area for BioLife Solutions' bioproduction products and services, was valued at $17.1 billion in 2022 and is expected to reach $81.2 billion by 2030.
The global regenerative medicine market is anticipated to reach $180.1 billion by 2026.
The stem cell preservation market is experiencing an annual growth rate of 13.2%.
In the U.S., BioLife Solutions' biopreservation media holds a market share of over 70% in approximately 250 ongoing commercially sponsored clinical trials.

BioLife Solutions' main products and services include cell processing solutions such as biopreservation media (e.g., CryoStor and HypoThermosol FRS), human platelet lysates, cryogenic vials, automated cell-processing fill machines, and automated thawing devices (ThawSTAR line).

AI Analysis | Feedback

BioLife Solutions (BLFS) is expected to drive future revenue growth over the next 2-3 years through several key strategies:

Growth in Cell Processing Platform and Biopreservation Media: The company's cell processing platform, particularly its biopreservation media, is consistently highlighted as a primary revenue driver. For instance, in Q1 2025, the cell processing platform's 33% year-over-year increase primarily drove the 30% overall revenue increase, and similar trends were seen in Q2 and Q3 2025. BioLife Solutions anticipates its cell processing platform to contribute significantly to its total revenue, with projected growth rates of 18% to 21% over 2024 for this segment. This platform supports a substantial portion of ongoing clinical trials for cell and gene therapies in the U.S., positioning it for continued expansion with future product approvals and geographic market penetration.
Increased Demand from Commercial Cell and Gene Therapy Customers: A significant portion of the growth in biopreservation media revenue is attributed to strong demand from commercial customers utilizing approved cell and gene therapies. The company's strategic alignment as a "pure play enabler of CGT's globally" benefits from favorable secular trends, including an increasing number of therapy approvals and expanding indications.
Strategic Focus on Core Competencies through Divestitures: BioLife Solutions has strategically divested non-core assets, such as the SciSafe biostorage business and the evo cold chain logistics product line, to sharpen its focus on its high-growth, high-margin cell processing portfolio. This streamlining is expected to enhance both top-line growth and margin expansion by concentrating resources on proprietary biopreservation media and related products.
Introduction of New, Innovative Products and Technologies: The company expands its biopreservation portfolio through strategic acquisitions, such as PanTHERA CryoSolutions in April 2025. This acquisition adds proprietary Ice Recrystallization Inhibitor technology, enhancing BioLife's scientific capabilities and product offerings within the bioproduction consumables market.
Anticipated Price Increases: During a Q3 2025 earnings call, executives indicated plans for a 4-6% price increase in 2026, which could further contribute to revenue growth.

AI Analysis | Feedback

Share Issuance

BioLife Solutions announced a proposed underwritten public offering of common stock on July 1, 2020.
The company intended to use the net proceeds from this offering for general corporate purposes, including potential investments in or acquisitions of synergistic or complementary companies, and working capital.
As of October 30, 2025, BioLife Solutions had 48.1 million shares issued and outstanding.

Outbound Investments

In April 2025, BioLife Solutions acquired PanTHERA CryoSolutions for $9.3 million in cash and 241,355 shares of its common stock, aiming to enhance its biopreservation media portfolio.
BioLife Solutions acquired SciSafe, a biostorage provider, for $30 million in October 2020, which included $15 million in cash and $15 million in stock.
The company made a strategic investment in Pluristyx on July 28, 2025.

Capital Expenditures

Capital expenditures for the first quarter of 2025 were $1 million.
Cash usage in Q1 2025 was notably influenced by capital expenditures, alongside unfavorable working capital and debt principal payments.
The company anticipates adding some capital expenditures in 2026, but is exercising caution until a clear return on investment is evident.

Better Bets than BioLife Solutions (BLFS)

INDUSTRY: Health Care Supplies

Higher Rev Chg 3Y Avg | Lower P/S (Values for BLFS: 9.3% | 11.9x)

LNTH (25.5% | 2.9x)

Lantheus

NEOG (23.2% | 1.7x)

Neogen

Higher Rev Chg 3Y Avg (Value for BLFS: 9.3%)

LNTH (25.5%)

Lantheus

NEOG (23.2%)

Neogen

Higher Op Mgn LTM (Value for BLFS: -20.0%)

LNTH (22.9%)

Lantheus

WST (20.9%)

West Pharmaceutical Services

COO (16.7%)

Cooper Companies

ALGN (15.2%)

Align Technology

MMSI (11.4%)

Merit Medical Systems

Higher CFO/Rev LTM (Value for BLFS: 16.8%)

LNTH (30.0%)

Lantheus

WST (23.0%)

West Pharmaceutical Services

HAE (21.8%)

Haemonetics

COO (19.5%)

Cooper Companies

MMSI (18.1%)

Merit Medical Systems

Higher FCF/Rev LTM (Value for BLFS: 10.5%)

LNTH (24.9%)

Lantheus

ALGN (14.2%)

Align Technology

MMSI (13.8%)

Merit Medical Systems

WST (12.6%)

West Pharmaceutical Services

COO (10.6%)

Cooper Companies

Higher Total Yield (Value for BLFS: -0.3%)

LNTH (3.7%)

Lantheus

ALGN (3.3%)

Align Technology

WST (2.6%)

West Pharmaceutical Services

COO (2.3%)

Cooper Companies

MMSI (2.3%)

Merit Medical Systems

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for BLFS: 9.3% | 11.9x)

UNH (11.4% | 0.7x)

UnitedHealth

AMGN (11.2% | 5.0x)

Amgen

BSX (15.6% | 7.4x)

Boston Scientific

SYK (10.8% | 5.6x)

Stryker

VRTX (10.5% | 10.1x)

Vertex Pharmaceuticals

Higher Rev Chg LTM (Value for BLFS: 87.5%)

ARWR (23258.2%)

Arrowhead Pharmaceuticals

CYTK (2609.3%)

Cytokinetics

MDGL (864.2%)

Madrigal Pharmaceuticals

RNA (106.3%)

Avidity Biosciences

PTCT (97.5%)

PTC Therapeutics

Higher Rev Chg 3Y Avg (Value for BLFS: 9.3%)

LLY (23.4%)

Eli Lilly

ISRG (16.3%)

Intuitive Surgical

BSX (15.6%)

Boston Scientific

UNH (11.4%)

UnitedHealth

AMGN (11.2%)

Amgen

Higher Op Mgn LTM (Value for BLFS: -20.0%)

LLY (43.0%)

Eli Lilly

MRK (34.9%)

Merck

JNJ (26.2%)

Johnson & Johnson

ABBV (24.1%)

AbbVie

UNH (6.1%)

UnitedHealth

Higher CFO/Rev LTM (Value for BLFS: 16.8%)

ABBV (35.0%)

AbbVie

MRK (26.6%)

Merck

JNJ (26.3%)

Johnson & Johnson

LLY (20.5%)

Eli Lilly

TMO (17.5%)

Thermo Fisher Scientific

Higher FCF/Rev LTM (Value for BLFS: 10.5%)

ABBV (33.0%)

AbbVie

MRK (20.3%)

Merck

JNJ (20.3%)

Johnson & Johnson

ABT (15.8%)

Abbott Laboratories

TMO (14.0%)

Thermo Fisher Scientific

Higher Total Yield (Value for BLFS: -0.3%)

MRK (10.2%)

Merck

UNH (8.5%)

UnitedHealth

JNJ (7.5%)

Johnson & Johnson

ABBV (3.4%)

AbbVie

LLY (1.9%)

Eli Lilly

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for BLFS: 9.3% | 11.9x)

GOOGL (11.0% | 9.8x)

Alphabet

AMZN (11.3% | 3.7x)

Amazon.com

META (17.3% | 8.8x)

Meta Platforms

BRK-B (19.8% | 2.7x)

Berkshire Hathaway

JPM (13.4% | 5.0x)

JPMorgan Chase

Higher Rev Chg LTM (Value for BLFS: 87.5%)

CRWV (235.4%)

CoreWeave

CRDO (224.2%)

Credo Technology

EXE (169.1%)

Expand Energy

DLTR (156.4%)

Dollar Tree

ALAB (136.5%)

Astera Labs

Higher Rev Chg 3Y Avg (Value for BLFS: 9.3%)

NVDA (91.6%)

NVIDIA

META (17.3%)

Meta Platforms

MSFT (13.2%)

Microsoft

AMZN (11.3%)

Amazon.com

GOOGL (11.0%)

Alphabet

Higher Op Mgn LTM (Value for BLFS: -20.0%)

NVDA (58.8%)

NVIDIA

MSFT (46.3%)

Microsoft

GOOGL (32.2%)

Alphabet

AAPL (31.9%)

Apple

AMZN (11.4%)

Amazon.com

Higher CFO/Rev LTM (Value for BLFS: 16.8%)

MSFT (50.0%)

Microsoft

NVDA (44.4%)

NVIDIA

GOOGL (39.3%)

Alphabet

AAPL (26.6%)

Apple

AMZN (18.1%)

Amazon.com

Higher FCF/Rev LTM (Value for BLFS: 10.5%)

NVDA (41.3%)

NVIDIA

MSFT (26.6%)

Microsoft

META (23.7%)

Meta Platforms

AAPL (23.5%)

Apple

GOOGL (19.1%)

Alphabet

Higher Total Yield (Value for BLFS: -0.3%)

MSFT (3.6%)

Microsoft

GOOGL (3.5%)

Alphabet

AMZN (2.9%)

Amazon.com

AAPL (2.8%)

Apple

NVDA (2.2%)

NVIDIA

		Best Bets In Health Care Sector
	BLFS	RPRX	HALO	DOCS	CPRX	HRMY	LGND	ISRG	GMED	MD	HIMS
What You Pay
P/E	-372.2	22.1	13.6	32.4	13.7	11.8	78.9	75.0	28.1	11.4	58.0
P/EBIT	-59.5	10.7	10.6	33.2	11.5	8.9	57.4	73.2	27.4	7.7	67.5
What You Get
Rev Chg Q	31.2%	7.9%	22.1%	23.2%	15.3%	28.7%	122.8%	22.9%	22.9%	-3.6%	49.2%
Rev Chg LTM	87.5%	3.7%	31.2%	20.2%	25.6%	21.1%	64.8%	22.2%	11.7%	-4.2%	78.0%
Rev Chg 3Y Avg	9.3%	1.5%	29.0%	17.4%	46.5%	27.4%	16.0%	16.3%	45.6%	-0.5%	71.0%
FCF/Rev 3Y Avg	-4.3%	115.2%	45.0%	42.7%	34.2%	33.2%	23.9%	16.5%	14.3%	8.9%	6.9%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	BioLife Solutions Earnings Notes
2	How Low Can BioLife Solutions Stock Really Go?	Return
3	Why BioLife Solutions Stock Moved: BLFS Stock Has Gained 54% Since 2023 Fiscal End, Primarily Due To Favorable Change In Price To Sales Multiple (P/S)
4	BLFS Dip Buy Analysis
5	Now Is Not The Time To Buy BioLife Solutions Stock	Buy or Fear
6	BioLife Solutions (BLFS) Valuation Ratios Comparison	Financials
7	BioLife Solutions Total Shareholder Return (TSR): 59.8% in 2024 and -11.4% 3-yr compounded annual returns (above peer average)
8	BioLife Solutions (BLFS) Operating Cash Flow Comparison	Financials
9	BioLife Solutions (BLFS) Net Income Comparison	Financials
10	BioLife Solutions (BLFS) Operating Income Comparison	Financials

	Title
0	ARTICLES

Trade Ideas

Select ideas related to BLFS. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	21.4%	21.4%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.4%	-7.4%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	18.0%	18.0%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.9%	3.9%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	12.2%	12.2%	-5.1%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
ZETA	Zeta Global	4.6	8.3%	15.1%
SGML	Sigma Lithium	1.6	7.3%	29.2%
USAS	Americas Gold And Silver	1.6	6.6%	557.6%
CPNG	Coupang	44.2	6.4%	10.4%
LION	Lionsgate Studios	2.7	4.6%	-69.9%
BBW	Build-A-Bear Workshop	0.8	4.4%	37.8%
XRAY	Dentsply Sirona	2.3	4.2%	-36.3%
BLMN	Bloomin Brands	0.6	3.8%	-41.2%
FUN	Six Flags Entertainment	1.5	3.8%	-69.1%
SVM	Silvercorp Metals	1.9	3.6%	198.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FLY	Firefly Aerospace	3.3	-13.7%	-61.3%
TMC	TMC The Metals	2.5	-10.5%	508.9%
ORGO	Organogenesis	0.7	-10.1%	64.8%
AAOI	Applied Optoelectronics	2.4	-9.3%	0.8%
BKSY	BlackSky Technology	0.7	-9.0%	79.0%
LUNR	Intuitive Machines	1.8	-8.7%	-16.0%
RCAT	Red Cat	0.8	-8.7%	-35.4%
RGTI	Rigetti Computing	6.7	-8.7%	46.7%
RDW	Redwire	1.0	-8.6%	-56.6%
RKLB	Rocket Lab	36.4	-8.5%	177.4%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
OMER	Omeros	0.9	71.5%	59.0%
RZLT	Rezolute	0.3	44.3%	-45.5%
DVAX	Dynavax Technologies	1.8	41.5%	20.4%
LUNR	Intuitive Machines	1.8	40.6%	-16.0%
UAMY	United States Antimony	0.7	39.0%	252.5%
FOLD	Amicus Therapeutics	4.4	30.9%	51.3%
ADEA	Adeia	1.9	30.3%	23.0%
HUT	Hut 8	5.2	28.6%	142.3%
AAOI	Applied Optoelectronics	2.4	27.1%	0.8%
SGML	Sigma Lithium	1.6	24.9%	29.2%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TPL	Texas Pacific Land	6.6	-67.9%	-21.5%
LW	Lamb Weston	5.9	-29.0%	-35.3%
TLRY	Tilray Brands	10.2	-22.2%	-27.8%
TDUP	ThredUp	0.8	-18.2%	348.2%
LAB	Standard BioTools	0.5	-16.9%	-21.1%
OLMA	Olema Pharmaceuticals	2.2	-14.9%	349.9%
EVEX	Eve	1.4	-12.0%	-21.9%
IRON	Disc Medicine	2.8	-11.2%	26.7%
AVO	Mission Produce	0.8	-11.1%	-18.8%
CABO	Cable One	0.7	-10.6%	-67.4%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
TLRY	Tilray Brands	10.2	876.4%	-27.8%
HPP	Hudson Pacific Properties	4.7	452.7%	-51.0%
WVE	WAVE Life Sciences	2.9	139.2%	43.7%
TE	T1 Energy	1.1	106.7%	400.0%
VERA	Vera Therapeutics	3.4	82.1%	26.7%
OMER	Omeros	0.9	66.2%	59.0%
RKLB	Rocket Lab	36.4	65.8%	177.4%
PL	Planet Labs PBC	5.9	65.0%	379.2%
AAOI	Applied Optoelectronics	2.4	63.5%	0.8%
LUNR	Intuitive Machines	1.8	62.4%	-16.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
RZLT	Rezolute	0.3	-72.0%	-45.5%
JANX	Janux Therapeutics	0.9	-59.0%	-73.4%
FRMI	Fermi	5.3	-46.0%	-76.6%
LENZ	LENZ Therapeutics	0.5	-43.5%	-41.6%
GOGO	Gogo	0.6	-35.3%	-43.0%
HPK	HighPeak Energy	0.5	-33.9%	-70.4%
PACB	Pacific Biosciences of California	0.5	-32.7%	-3.3%
LDI	loanDepot	0.4	-29.6%	3.9%
ORIC	ORIC Pharmaceuticals	0.6	-29.0%	2.2%
LW	Lamb Weston	5.9	-28.6%	-35.3%

Peer Comparisons for BioLife Solutions

Peers to compare with:

Financials

	BLFS	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	BioLife .	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Price	24.90	23.26	24.49	305.09	78.16	273.40	51.53
Mkt Cap	1.2	21.9	32.6	284.9	309.2	4,074.4	158.8
Rev LTM	100	55,295	34,296	65,402	57,696	408,625	56,496
Op Inc LTM	-20	3,624	1,644	11,544	12,991	130,214	7,584
FCF LTM	11	2,800	627	11,854	12,733	96,184	7,327
FCF 3Y Avg	-0	2,978	1,400	11,753	13,879	100,503	7,366
CFO LTM	17	3,697	2,919	13,483	13,744	108,565	8,590
CFO 3Y Avg	6	3,672	3,896	13,498	14,736	111,559	8,697

Growth & Margins

	BLFS	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	BioLife .	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Rev Chg LTM	87.5%	3.2%	13.8%	4.5%	8.9%	6.0%	7.4%
Rev Chg 3Y Avg	9.3%	-3.9%	6.5%	2.6%	3.7%	1.8%	3.2%
Rev Chg Q	31.2%	4.2%	14.4%	9.1%	7.5%	9.6%	9.4%
QoQ Delta Rev Chg LTM	7.1%	1.1%	3.7%	2.1%	1.8%	2.1%	2.1%
Op Mgn LTM	-20.0%	6.6%	4.8%	17.7%	22.5%	31.9%	12.1%
Op Mgn 3Y Avg	-17.8%	7.4%	7.2%	16.4%	24.2%	30.8%	11.9%
QoQ Delta Op Mgn LTM	1.8%	-0.2%	-1.4%	0.6%	0.4%	0.1%	0.2%
CFO/Rev LTM	16.8%	6.7%	8.5%	20.6%	23.8%	26.6%	18.7%
CFO/Rev 3Y Avg	6.6%	6.8%	12.7%	21.4%	26.1%	28.4%	17.1%
FCF/Rev LTM	10.5%	5.1%	1.8%	18.1%	22.1%	23.5%	14.3%
FCF/Rev 3Y Avg	-4.3%	5.5%	4.6%	18.6%	24.6%	25.6%	12.1%

Valuation

	BLFS	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	BioLife .	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Cap	1.2	21.9	32.6	284.9	309.2	4,074.4	158.8
P/S	11.9	0.4	1.0	4.4	5.4	10.0	4.9
P/EBIT	-59.5	6.8	19.9	25.1	22.5	31.3	21.2
P/E	-372.2	8.6	572.7	36.0	29.9	41.0	33.0
P/CFO	70.8	5.9	11.2	21.1	22.5	37.5	21.8
Total Yield	-0.3%	14.1%	2.3%	5.0%	5.4%	2.8%	3.9%
Dividend Yield	0.0%	2.5%	2.1%	2.2%	2.1%	0.4%	2.1%
FCF Yield 3Y Avg	-0.5%	10.6%	5.5%	6.4%	6.0%	3.1%	5.7%
D/E	0.0	0.5	0.7	0.2	0.1	0.0	0.2
Net D/E	-0.0	0.3	0.6	0.2	0.0	0.0	0.1

Returns

	BLFS	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	BioLife .	HP	Hewlett .	Internat.	Cisco Sy.	Apple
1M Rtn	-6.7%	-1.8%	14.4%	0.6%	2.7%	-1.5%	-0.4%
3M Rtn	0.8%	-11.9%	2.7%	7.9%	17.0%	7.1%	4.9%
6M Rtn	15.9%	-4.0%	34.5%	6.6%	15.2%	36.3%	15.5%
12M Rtn	-6.4%	-27.0%	16.2%	40.5%	34.5%	7.5%	11.8%
3Y Rtn	46.9%	-1.9%	71.1%	143.1%	81.3%	120.2%	76.2%
1M Excs Rtn	-10.2%	-5.6%	12.9%	-2.2%	-0.0%	-3.7%	-3.0%
3M Excs Rtn	-3.5%	-16.2%	-1.7%	3.6%	12.7%	2.8%	0.6%
6M Excs Rtn	3.6%	-16.3%	22.3%	-5.7%	3.0%	24.0%	3.3%
12M Excs Rtn	-21.6%	-42.9%	-0.7%	25.0%	19.9%	-8.4%	-4.6%
3Y Excs Rtn	-46.4%	-83.5%	-11.2%	59.6%	-1.2%	28.4%	-6.2%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	11/6/2025	3/3/2025	2/29/2024	3/31/2023	3/31/2022	3/31/2021	5/15/2020
Key Financials
Total Revenue	100	82	76	76	119	48	27
EBITDA	-14	2	-13	6	-18	1	3
Operating Income	-20	-7	-26	-11	-31	-4	1
Net Income	-3	-20	-68	-140	-9	2	-2
EPS	-0.06	-0.44	-1.55	-3.29	-0.23	0.07	-0.09
Growth Rates
Total Revenue Growth	87.5%	8.4%	-0.5%	-36.0%	147.8%	75.7%	38.6%
EBITDA Growth	-295.1%	111.5%	-330.2%	132.6%	-1762.1%	-58.3%	110.4%
Operating Income Growth	-719.1%	72.2%	-140.1%	65.2%	-666.6%	-619.2%	-79.0%
Net Income Growth	93.3%	70.3%	51.4%	-1469.4%	-549.2%	219.7%	93.4%
Margins
EBITDA Margin	-14.2%	1.9%	-17.6%	7.6%	-14.9%	2.2%	9.4%
Operating Income Margin	-20.0%	-8.7%	-33.8%	-14.0%	-25.7%	-8.3%	2.8%
Net Income Margin	-3.2%	-24.5%	-89.6%	-183.4%	-7.5%	4.1%	-6.1%
Cash & Debt
Total Cash	79	105	44	63	70	90	6
Total Debt	21	30	34	44	27	11	1
Net Debt / (Cash)	-58	-74	-10	-19	-43	-79	-5
Cash Flows
Net Cash from Operations	17	8	-12	-8	-5	7	1
Free Cash from Operations	11	5	-19	-19	-13	2	1
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022
Filing Date	11/6/2025	8/7/2025	5/8/2025	3/3/2025	11/12/2024	8/9/2024	5/10/2024	2/29/2024	11/9/2023	8/9/2023	5/11/2023	3/31/2023
Key Financials Quarterly
Total Revenue	28	25	24	23	21	20	18	-6	24	29	38	-41
Ebitda	1	-15	0	-0	2	1	-1	5	-12	-2	-10	88
Operating Income	-0	-17	-1	-2	-0	-1	-3	3	-9	-12	-13	19
Net Income	1	-16	-0	12	-2	-21	-10	-15	-29	-10	-14	-49
EPS	0.01	-0.33	-0.01	0.27	-0.04	-0.45	-0.22	-0.33	-0.67	-0.23	-0.32	-1.15
Key Financials TTM
Total Revenue TTM	100	93	88	82	53	56	65	84	49	66	78	76
Ebitda TTM	-14	-14	3	2	7	-7	-9	-18	64	70	-1	6
Operating Income TTM	-20	-20	-5	-7	-2	-11	-21	-31	-14	-15	-12	-11
Net Income TTM	-3	-6	-10	-20	-48	-75	-65	-68	-102	-83	-146	-140
Growth Rates Quarterly
Total Revenue Growth	31.2%	28.9%	29.9%	470.1%	-9.3%	-32.6%	-51.1%	85.1%	-42.1%	-27.9%	4.1%	-210.6%
EBITDA Growth	-34.4%	-1545.2%	116.3%	-107.6%	115.9%	163.1%	89.9%	-93.9%	-81.5%	97.7%	-202.1%	821.7%
Operating Income Growth	78.7%	-1174.3%	63.0%	-182.1%	95.2%	88.7%	74.4%	-86.5%	6.9%	-28.0%	-14.1%	214.3%
Net Income Growth	136.5%	23.6%	95.6%	183.3%	94.2%	-103.1%	25.5%	69.6%	-182.4%	86.0%	-84.8%	-212.4%
Margins Quarterly
EBITDA Margin	4.4%	-60.0%	0.7%	-1.8%	8.9%	5.4%	-5.5%	-	-50.7%	-5.7%	-26.6%	-
Operating Income Margin	-0.3%	-65.5%	-5.1%	-9.3%	-2.0%	-6.6%	-17.9%	-	-37.1%	-39.5%	-34.2%	-
Net Income Margin	2.2%	-62.3%	-1.9%	54.8%	-8.0%	-105.1%	-55.4%	-	-123.6%	-34.9%	-36.4%	-
Cash & Debt
Total Cash	79	82	89	105	34	34	45	44	41	46	55	63
Total Debt	21	24	27	30	39	36	41	34	44	45	43	44
Net Debt / (Cash)	-58	-58	-62	-74	5	2	-4	-10	3	-2	-12	-19
Cash Flows Quarterly
FCF from Operations	6	7	2	2	5	6	-4	2	-4	-8	-3	8
Cash Flows TTM
FCF from Operations TTM	17	16	15	8	9	-0	-14	-12	-7	-1	-3	-8
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-0.0%	-10.4%	-0.8%	-1.4%	-0.2%	-0.8%	-2.0%	1.6%	-5.5%	-7.4%	-8.5%	12.9%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-3.1%	-3.2%	-0.8%	-1.2%	-0.4%	-1.6%	-3.2%	-4.8%	-2.2%	-2.4%	-1.1%	-1.8%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Cell processing	66
Evo and thaw	10
Product revenue		136	102	45	27
Rental revenue		10	7	2	1
Service revenue		15	10	2
Total	76	162	119	48	27

Price Behavior

Price Behavior

Market Price	$24.90
Market Cap ($ Bil)	1.2
First Trading Date	05/26/1992
Distance from 52W High	-13.5%
	50 Days	200 Days
DMA Price	$26.08	$24.25
DMA Trend	indeterminate	down
Distance from DMA	-4.5%	2.7%
	3M	1YR
Volatility	37.7%	49.7%
Downside Capture	169.14	160.60
Upside Capture	139.21	129.35
Correlation (SPY)	45.3%	51.8%

BLFS Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	1.54	1.40	1.41	1.98	1.34	1.57
Up Beta	2.03	1.48	1.76	2.37	1.23	1.37
Down Beta	-0.91	0.96	0.75	1.07	1.27	1.62
Up Capture	174%	167%	164%	257%	172%	475%
Bmk +ve Days	12	25	38	73	141	426
Stock +ve Days	7	17	29	61	116	369
Down Capture	175%	145%	158%	203%	129%	110%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	11	23	32	61	129	372

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

		Comparison of BLFS With Other Asset Classes (Last 1Y)
	BLFS	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-9.1%	15.1%	17.8%	72.1%	8.6%	4.4%	-8.2%
Annualized Volatility	49.5%	17.2%	19.4%	19.3%	15.2%	17.0%	35.0%
Sharpe Ratio	-0.03	0.65	0.72	2.70	0.34	0.09	-0.08
Correlation With Other Assets		45.9%	51.3%	-7.9%	9.2%	39.7%	28.2%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of BLFS With Other Asset Classes (Last 5Y)
	BLFS	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-10.4%	8.4%	14.7%	18.7%	11.5%	4.6%	30.8%
Annualized Volatility	67.0%	14.5%	17.1%	15.5%	18.7%	18.9%	48.6%
Sharpe Ratio	0.12	0.40	0.70	0.97	0.50	0.16	0.57
Correlation With Other Assets		36.1%	46.4%	6.4%	5.1%	40.2%	24.4%

Based On 10-Year Data

		Comparison of BLFS With Other Asset Classes (Last 10Y)
	BLFS	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	27.5%	9.9%	14.8%	15.3%	7.0%	5.3%	69.2%
Annualized Volatility	68.2%	16.6%	18.0%	14.7%	17.6%	20.8%	55.8%
Sharpe Ratio	0.65	0.49	0.71	0.86	0.32	0.22	0.90
Correlation With Other Assets		30.2%	37.4%	3.3%	7.5%	29.6%	15.9%

Short Interest

Short Interest: As Of Date	12152025
Short Interest: Shares Quantity	2,780,414
Short Interest: % Change Since 11302025	-4.8%
Average Daily Volume	278,027
Days-to-Cover Short Interest	10
Basic Shares Quantity	47,925,038
Short % of Basic Shares	5.8%

Returns Analyses

	Title
0	How Low Can BioLife Solutions Stock Really Go?

Insider Activity

Expand for Morenull

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

BioLife Solutions (BLFS)

Market Price (12/28/2025): $24.89 | Market Cap: $1.2 BilSector: Health Care | Industry: Health Care Supplies

BioLife Solutions (BLFS)

Market Price (12/28/2025): $24.89Market Cap: $1.2 BilSector: Health CareIndustry: Health Care Supplies

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

BLFS Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About BioLife Solutions (BLFS)

Share Issuance

Outbound Investments

Capital Expenditures

Interactive Breakdown

Better Bets than BioLife Solutions (BLFS)

INDUSTRY: Health Care Supplies

Higher Rev Chg 3Y Avg | Lower P/S (Values for BLFS: 9.3% | 11.9x)

Higher Rev Chg 3Y Avg (Value for BLFS: 9.3%)

Higher Op Mgn LTM (Value for BLFS: -20.0%)

Higher CFO/Rev LTM (Value for BLFS: 16.8%)

Higher FCF/Rev LTM (Value for BLFS: 10.5%)

Higher Total Yield (Value for BLFS: -0.3%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for BLFS: 9.3% | 11.9x)

Higher Rev Chg LTM (Value for BLFS: 87.5%)

Higher Rev Chg 3Y Avg (Value for BLFS: 9.3%)

Higher Op Mgn LTM (Value for BLFS: -20.0%)

Higher CFO/Rev LTM (Value for BLFS: 16.8%)

Higher FCF/Rev LTM (Value for BLFS: 10.5%)

Higher Total Yield (Value for BLFS: -0.3%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for BLFS: 9.3% | 11.9x)

Higher Rev Chg LTM (Value for BLFS: 87.5%)

Higher Rev Chg 3Y Avg (Value for BLFS: 9.3%)

Higher Op Mgn LTM (Value for BLFS: -20.0%)

Higher CFO/Rev LTM (Value for BLFS: 16.8%)

Higher FCF/Rev LTM (Value for BLFS: 10.5%)

Higher Total Yield (Value for BLFS: -0.3%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for BioLife Solutions

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Financials

Segment Financials

Market Price (12/28/2025): $24.89 | Market Cap: $1.2 Bil
Sector: Health Care | Industry: Health Care Supplies

Market Price (12/28/2025): $24.89
Market Cap: $1.2 Bil
Sector: Health Care
Industry: Health Care Supplies